NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
61919-0465-60 | 61919-0465 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
61919-0827-15 | 61919-0827 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 15, 2020 | In Use | |
61919-0827-21 | 61919-0827 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 15, 2020 | In Use | |
61919-0986-10 | 61919-0986 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
61919-0986-30 | 61919-0986 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
62112-8068-01 | 62112-8068 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 10, 2002 | In Use | |
62112-8068-02 | 62112-8068 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 10, 2002 | In Use | |
62135-0490-30 | 62135-0490 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 17, 2022 | In Use | ||
62135-0491-30 | 62135-0491 | Letrozole | LETROZOLE | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 17, 2022 | In Use | ||
62332-0565-30 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
62332-0565-90 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
62484-0020-01 | 62484-0020 | Purixan | Purixan | 20.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Oral | Apr 28, 2014 | In Use | |
62484-0020-02 | 62484-0020 | Purixan | Purixan | 20.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Oral | Apr 28, 2014 | In Use | |
62559-0173-31 | 62559-0173 | Nilutamide | Nilutamide | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jul 18, 2016 | In Use | |
62559-0670-30 | 62559-0670 | Anastrozole | ARIMIDEX | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 26, 2018 | In Use | ||
53217-0300-60 | 53217-0300 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
62559-0680-30 | 62559-0680 | Bicalutamide | CASODEX | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jun 26, 2018 | In Use | |
62559-0890-30 | 62559-0890 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct 26, 2020 | In Use | |
62559-0920-14 | 62559-0920 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | In Use | |
62559-0920-51 | 62559-0920 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | In Use | |
71329-0305-01 | 71329-0305 | Methylprednisolone | Methylprednisolone Sodium Succinate | 2.0 g/30.6mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Apr 20, 2021 | In Use | |
62756-0356-66 | 62756-0356 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 2, 2007 | In Use | |
62756-0356-83 | 62756-0356 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 2, 2007 | In Use | |
62756-0452-36 | 62756-0452 | Octreotide acetate | BYNFEZIA Pen | 2.5 mg/mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Apr 29, 2020 | In Use | ||
62756-0452-37 | 62756-0452 | Octreotide acetate | BYNFEZIA Pen | 2.5 mg/mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Apr 29, 2020 | In Use |
Found 11120 results — Export these results